Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.

Keita NinagawaMasaru KatoSatonori TsunetaSuguru IshizakaHideyuki UjiieRyo HisadaMichihito KonoYuichiro FujiedaYoichi M ItoTatsuya Atsumi

Published in: Rheumatology (Oxford, England) (2022)

Our data indicate beneficial signals of nintedanib on cardiomyopathy associated with SSc. The anti-fibrotic effect of nintedanib might not be limited to the lung.

Keyphrases

systemic sclerosis
interstitial lung disease
idiopathic pulmonary fibrosis
heart failure
rheumatoid arthritis
electronic health record
big data
deep learning